Monitoring the safety of new treatments for atopic dermatitis in diverse populations
New approaches to safety monitoring of novel systemic treatments for atopic dermatitis in clinical practice and underrepresented populations
This study is looking at how safe new treatments for severe eczema are, especially for people who might not always be included in research, and it wants to use health data from millions of Americans to help spot any side effects and make better treatment choices for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11002316 on NIH RePORTER |
What this research studies
This research investigates the safety of new immuno-modulating drugs for treating severe atopic dermatitis, particularly in underrepresented populations. It aims to create a monitoring system that uses existing healthcare data to identify potential side effects and improve treatment decisions. By analyzing data from over 78 million Americans, including children and women of childbearing age, the study seeks to provide insights that reflect real-world clinical practice rather than just clinical trial results.
Who could benefit from this research
Good fit: Ideal candidates include children and women of reproductive age suffering from severe atopic dermatitis.
Not a fit: Patients with mild atopic dermatitis or those not using immuno-modulating drugs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatment options for patients with atopic dermatitis.
How similar studies have performed: Previous research has shown success in using healthcare databases for safety monitoring, making this approach promising yet still innovative in its specific application to atopic dermatitis.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Schneeweiss, Sebastian G. — Brigham and Women's Hospital
- Study coordinator: Schneeweiss, Sebastian G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.